TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02846376
Drug: Ipilimumab
Normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ipilimumab is a recombinant, human mAb that binds to the cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4). Ipilimumab is an immunoglobulin 1 (IgG1) kappa immunoglobulin with an approximate molecular weight of 148 kilo-Daltons (kDa). Ipilimumab is produced in mammalian (Chinese hamster ovary) cell culture.
Study: NCT04438603
Drug: Intervention for incipient patients at low risk of disease progression
Normalized name: rose bengal AT
DrugBank: Rose bengal (DB11182)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conservative treatment, if necessary use ACEI/ARB and titrated to the maximum tolerated dose, with a BP-lowering goal of \< 130/80 mm Hg
Study: NCT04438603
Drug: Intervention for patients at high risk of disease progression
Normalized name: rose bengal AT
DrugBank: Rose bengal (DB11182)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: BP-lowering goal of \< 125/75 mm Hg and treat with steroids or steroids combined with immunosuppressants based on optimal supportive therapy:~1. If GFR\>60 ml/min/1.73m\^2, oral prednisone 0.6-0.8 mg/kg/day ( (maximum dose 48 mg/day) for 2 months, followed by a monthly dose reduction of 8 mg for 24 weeks.~2. If GFR is 30-60 ml/min/1.73m\^2, intravenous cyclophosphamide (CTX) 750 mg per month per m\^2 for 6 months, along with oral prednisone (at the same dose as 1); if intravenous administration is unacceptable, then the above regimen was replaced with oral mycophenolate mofetil 500 mg bid for 24 weeks.
Study: NCT03415477
Drug: Denosumab (Xgeva)
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab (Xgeva) 120 mg was given subcutaneously (abdomen wall or upper arms) every 4 weeks (Q4W), with a loading dose on both Day 8 and Day15 of the first cycle， perioperatively.
Study: NCT03127215
Drug: Olaparib
Normalized name: Olaparib
DrugBank: Olaparib (DB09074)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Olaparib 150 mg tablet
Study: NCT03127215
Drug: Trabectedin
Normalized name: Trabectedin
DrugBank: Trabectedin (DB05109)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Trabectedin 1.1mg/m² infusional solution
Study: NCT02801097
Drug: RRx-001
Normalized name: RRx-001
DrugBank: RRx-001 (DB12060)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02801097
Drug: Irinotecan
Normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003636
Drug: carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003636
Drug: cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00109408
Drug: tocilizumab [RoActemra/Actemra]
DrugBank: Tocilizumab (DB06273)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 8mg/kg iv every 4 weeks
Study: NCT00456963
Drug: enalapril tablets
Normalized name: enalapril Oral Tablet
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one Enalapril 10mg tablet once daily for four weeks. Subsequentely one Enalapril 20mg tablet once daily until the end of the randomized treatment phase
Study: NCT00456963
Drug: Losartan Tablets
Normalized name: losartan Oral Tablet
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: one Losartan 50mg tablet once daily for four weeks. Subsequentely one Losartan 100mg tablet once daily until the end of the randomized treatment phase.
Study: NCT00541086
Drug: anastrozole
Normalized name: Anastrozole
DrugBank: Anastrozole (DB01217)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1 mg per day, orally
Study: NCT00541086
Drug: exemestane
Normalized name: Exemestane
DrugBank: Exemestane (DB00990)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg per day, orally
Study: NCT00541086
Drug: letrozole
Normalized name: Letrozole
DrugBank: Letrozole (DB01006)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2.5 mg per day, orally
Study: NCT00541086
Drug: tamoxifen citrate
Normalized name: Tamoxifen Citrate
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg per day, orally
Study: NCT02772354
Drug: Metoprolol
Normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antiarrhythmic therapy of premature ventricular complexes~Metoprolol 12-50 mg
Study: NCT02772354
Drug: Verapamil
Normalized name: Verapamil
DrugBank: Verapamil (DB00661)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Verapamil 20-240 mg
Study: NCT03196505
Drug: Bupivacaine
Normalized name: Bupivacaine
DrugBank: Bupivacaine (DB00297)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 60 milliliters (ml) of 0.25% bupivacaine diluted with 40 ml of saline for a total of 100 ml. After induction of anesthesia, the patients will receive 20 ml mixture locally infiltrated at each trocar incision site (5 sites).
Study: NCT02367170
Drug: Midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the event a subject shows signs of distress during the Bilateral phrenic nerve stimulation and measurement of transdiaphragmatic pressures, a dose of Midazolam is available. IV (in the vein) dose from 0.5 mg to 2 mg.
Study: NCT00851734
Drug: voclosporin ophthalmic solution
DrugBank: Voclosporin (DB11693)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.02%, 0.2% t.i.d. or b.i.d.
Study: NCT02469831
Drug: Rocuronium
Normalized name: Rocuronium
DrugBank: Rocuronium (DB00728)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01673724
Drug: pramipexole
Normalized name: Pramipexole
DrugBank: Pramipexole (DB00413)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: pramipexole
Study: NCT01673724
Drug: Bromocriptine
Normalized name: Bromocriptine
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: bromocriptine
Study: NCT00828087
Drug: Everolimus Eluting Coronary Stent System
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Everolimus Eluting Coronary Stent System (Everolimus Arm) implantation
Study: NCT00139854
Drug: Alprazolam orally disintegrating tablets
Normalized name: Alprazolam Orally Disintegrating Tablets
DrugBank: Alprazolam (DB00404)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02936505
Drug: Cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporin A (Sandimmun Neoral® or similar):~* Cyclosporin A given orally pretransplant in the dose of 2-3 mg/kg.~* Continued postop day 1 in the dose of 3mg/kgx2, according to local practice and blood concentration: 0-3 months 250-300; 3-6 months 200-250; 6-12 months 150-200; \>12 months 100-150 ng/ml. Cyclosporine A will be administered twice daily.
Study: NCT02936505
Drug: Mycophenolate mofetil (MMF)
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: MMF target dose: 2000 mg/day (1gx2):~o Controlled by a single Area Under the Curve (AUC) measurement day 90 with a target AUC between 40 and 60 mg.h/L and corrected accordingly.
Study: NCT02936505
Drug: Rabbit Anti thymocyte globulin
DrugBank: Rabbit (DB10415)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction therapy: Thymoglobulin® (Rabbit Anti thymocyte globulin)(1.5 mg/kg given immediately postoperatively).
Study: NCT02936505
Drug: Tacrolimus
Normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: * Tacrolimus should be given orally pretransplant in the dose of 0.1 mg/kg.~* Continued postop day 1 according to local practice and blood concentration: 0-3 months 10-14, 3-6 months 8-12, 6-12 months 8-10, \>12 months 6-8 ng/ml. Tacrolimus will be administered once daily.
Study: NCT01660841
Drug: Gadobutrol (Gadovist, BAY86-4875)
Normalized name: Gadobutrol
DrugBank: Gadobutrol (DB06703)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A single bolus injection of gadobutrol 1.0M 0.1mmol/kg body weight.
Study: NCT01094964
Drug: epirubicin hydrochloride
Normalized name: Epirubicin Hydrochloride
DrugBank: Epirubicin (DB00445)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01094964
Drug: mitomycin C
Normalized name: Mitomycin C
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00870948
Drug: ABT-874
Normalized name: ABT-925
DrugBank: ABT-384 (DB12501)
Approvals — FDA: no, EMA: no, PMDA: no
Description: See Arm Description for details regarding specific Intervention Description that is attributed to each Arm, respectively.
Study: NCT02288156
Drug: Capsaicin
Normalized name: Capsaicin
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: via nasal spray
Study: NCT02364193
Drug: Gd-CA
Normalized name: Gd-HPDO3A
DrugBank: Gadoteridol (DB00597)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bolus kinetic parameter analysis, different doses of Gd-CA (Dotarem by Guerbet) ranging between 0.1 and 0.5 mmol will be injected intravenously after dilution in 5 milliliter saline by an injector at a speed of 5 ml/s.
Study: NCT02834312
Drug: Estetrol
Normalized name: estetrol
DrugBank: Estetrol (DB12235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: All treatments (E4 \[2.5 mg, 5 mg, 10 mg, 15 mg\] capsule) will be administered once daily (QD) per os for at least 12 consecutive weeks until the last biological assessments (Day 90 maximum) have been performed.
Study: NCT00830037
Drug: Ferrous Sulfate
Normalized name: Ferrous Sulfate
DrugBank: Ferrous tartrate (DB13639)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral ferrous sulfate 325mg three times daily over 8 weeks. Further cycles of oral iron may be used based on periodic monitoring of iron stores.
Study: NCT03914820
Drug: Mitomycin
Normalized name: Mitomycin
DrugBank: Mitomycin (DB00305)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic surgery plus HIPEC CO2 performed with mitomycin
Study: NCT00364481
Drug: omeprazole
Normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02552355
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Daily administration of Metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4 during a 12 week exercise training program.
Study: NCT00326105
Drug: Quetiapine fumarate
Normalized name: Quetiapine Fumarate
DrugBank: Quetiapine (DB01224)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02680847
Drug: ALO-02
Normalized name: Aloe
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral/Capsule, twice per day dosing; Treatment duration consists of a 1 to 4 week Conversion/Titration Phase leading to a 2 to 4 week Maintenance Treatment duration.
Study: NCT02402192
Drug: Corifollitropin alfa
Normalized name: corifollitropin alfa
DrugBank: Corifollitropin alfa (DB09066)
Approvals — FDA: no, EMA: yes, PMDA: no
Study: NCT04547842
Drug: Mirtazapine 30 MG
Normalized name: mirtazapine 30 MG
DrugBank: Mirtazapine (DB00370)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mirtazapine is given in arm M to prevent PONV
Study: NCT04547842
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone is given in arm D to prevent PONV
Study: NCT00044382
Drug: CC-5013
Normalized name: CC
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02512692
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On days 1 and 8 of each cycle (21 days) Gemcitabine will be administered. Treatment may last up to 8 cycles
Study: NCT02512692
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On days 1 and 8 of each cycle (21 days) Cisplatin will be administered. Treatment may last up to 8 cycles
Study: NCT02985125
Drug: Everolimus
Normalized name: Everolimus
DrugBank: Everolimus (DB01590)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Treatment cycles are 28 days long. It is taken orally. On all arms, the dosage will be 2.5mg.
Study: NCT02181790
Drug: Acitretin
Normalized name: Acitretin
DrugBank: Acitretin (DB00459)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 17.5mg/d
Study: NCT03555539
Drug: Danicopan
Normalized name: Danicopan
DrugBank: Danicopan (DB15401)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet.
Study: NCT03814317
Drug: Inhaled Treprostinil
Normalized name: treprostinil Inhalation Solution
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Inhaled treprostinil causes dilatation of the pulmonary arteries and may help reduce the pulmonary pressures in this studied population.~All subjects will initiate inhaled treprostinil at a dose of 3 breaths (18 mcg) four times daily. Study drug doses escalations (additional one breath four times daily) can occur every three days with a maximum dosing regimen of up to 12 breaths (72 mcg) four times daily, as clinically tolerated.
Study: NCT00320385
Drug: Lapatinib
Normalized name: Lapatinib
DrugBank: Lapatinib (DB01259)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: oral lapatinib once daily
Study: NCT02345837
Drug: clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: ovulation induction by 100mg clomiphene citrate
Study: NCT00403637
Drug: indacaterol maleate
Normalized name: Indacaterol Maleate
DrugBank: Indacaterol (DB05039)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01070784
Drug: Symbicort Turbuhaler (Budesonide/formoterol)
Normalized name: budesonide / formoterol Metered Dose Inhaler [Symbicort]
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 x 160/4.5 microgram, inhalation, bid, 52 weeks
Study: NCT00886132
Drug: Sunitinib
Normalized name: Sunitinib
DrugBank: Sunitinib (DB01268)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 37.5 mg taken orally, daily every 28-day cycles
Study: NCT01780389
Drug: Open-label flexibly dosed milnacipran
Normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00854763
Drug: olmesartan
Normalized name: Olmesartan
DrugBank: Olmesartan (DB00275)
Approvals — FDA: no, EMA: no, PMDA: no
Description: olmesartan
Study: NCT03634605
Drug: Lidocaine 2% Injectable Solution
Normalized name: lidocaine 2% injectable solution
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01729364
Drug: crystalloid
Normalized name: Crystal ammonia
DrugBank: Ammonium carbonate (DB15926)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01729364
Drug: colloid
Normalized name: tin colloid
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00902174
Drug: imatinib mesylate
Normalized name: Imatinib Mesylate
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Two or 4 imatinib mesylate (QTI571) 100 mg film coated tablets once daily.
Study: NCT04628559
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: dexmedetomidine was administered as a gradual bolus of 1 µg/kg/10ml 10 min before induction of anesthesia and then as an infusion of 0.4 µg/kg per min (30 ml/h). In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).
Study: NCT04628559
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: In Group K, ketamine was administered as a 0.4 mg/kg/10ml IV bolus 10 min before induction of anesthesia and in the form of 10 µg/kg per min infusion after induction (30 ml/h).
Study: NCT04628559
Drug: Saline
Normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Group S was given a bolus of saline solution in 10 ml volume 10 min before induction of anesthesia, followed by 30 mL/h serum saline infusion.
Study: NCT00870272
Drug: Misoprostol
Normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 400mcg misoprostol taken sublingually or buccally
Study: NCT03135028
Drug: Entospletinib
Normalized name: Entospletinib
DrugBank: Entospletinib (DB12121)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg (2 × 200 mg tablets) orally twice daily
Study: NCT03135028
Drug: Daunorubicin
Normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 60 mg/m\^2 administered intravenously daily on Days 1 to 3 of each 28-day induction cycle
Study: NCT03135028
Drug: Cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg/m\^2 intravenous administration twice daily on Days 1 to 7 of each 28-day induction cycle~Hi-DAC: 3 g/m\^2 IV administration twice daily on days 1, 3, and 5 (≤ 60 years of age) or 1 g/m\^2 IV administration once daily on Days 1 to 5 (\> 60 years of age) of each 28-day post-remission cycle
Study: NCT00496873
Drug: Cytoxan
Normalized name: Cytoxan
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m\^2 on Day 1 of 21-day cycle.
Study: NCT00496873
Drug: Nipent
Normalized name: Nipent
DrugBank: Pentostatin (DB00552)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg/m\^2 on Day 1 of 21 Day Cycle.
Study: NCT00496873
Drug: Rituxan
Normalized name: Rituxan
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 375 mg/m\^2 on Day 1 of 21 Day Cycle.
Study: NCT00551291
Drug: Mycophenolate mofetil
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 gm twice daily orally until end of study.
Study: NCT00551291
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/day orally until end of study.
Study: NCT03736837
Drug: Anlotinib Plus Icotinib
Normalized name: Anlotinib
DrugBank: Icotinib (DB11737)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anlotinib：12mg/capsule, take once when limosis in the morning. If patients suffer from AEs, they can get declined dosage (10mg or 8mg).~Icotinib：125 mg/tablet，three times a day，fasting or serving with food. It should be continued until disease progression or intolerable toxicity or patients withdraw of consent.
Study: NCT02484573
Drug: Propanolol
Normalized name: Propanolol
DrugBank: Propranolol (DB00571)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00069082
Drug: Civamide (Zucapsaicin)
Normalized name: Capsaicin
DrugBank: Zucapsaicin (DB09120)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal Solution 0.01%
Study: NCT00069082
Drug: Sodium Chloride
Normalized name: Sodium Chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nasal Solution 10%
Study: NCT04532463
Drug: Amphotericin B 1 mg/kg 1 week & Flucytosine 100 mg/kg 1 week followed by Fluconazole 1200 mg/day 1 week
DrugBank: Fluconazole (DB00196)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: To study the clinical effectiveness and safety of amphotericin B with flucytosine-fluconazole therapy for cryptococcal meningitis in patients with HIV infection.
Study: NCT00942773
Drug: Voriconazole
Normalized name: Voriconazole
DrugBank: Voriconazole (DB00582)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03854344
Drug: Lidocaine Hydrochloride
Normalized name: Lidocaine Hydrochloride
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injected subcutaneously for skin graft harvesting
Study: NCT00426751
Drug: Abciximab
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous bolus of 0.25 mg/kg followed by continuous intravenous infusion of 0.125 mcg/kg/min (max. 10 mcg/min) for 12 h after PCI.
Study: NCT00426751
Drug: Eptifibatide
Normalized name: Eptifibatide
DrugBank: Eptifibatide (DB00063)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous bolus of 180 mcg/kg followed immediately by a continuous infusion of 2.0 mdg/kg/ min for 20-24 h after end of PCI, and a second bolus of 180 mcg/kg administered 10 min after the first bolus.
Study: NCT00843310
Drug: Lenalidomide (Revlimid)
Normalized name: Lenalidomide
DrugBank: Lenalidomide (DB00480)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00843310
Drug: Melphalan
Normalized name: Melphalan
DrugBank: Melphalan (DB01042)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00843310
Drug: Dexamethasone
Normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03765346
Drug: Oxycodone IR ADF
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone IR ADF manipulated/crushed (mass of 540 mg, containing oxycodone hydrochloride 30 mg), in a standardized procedure.
Study: NCT03765346
Drug: Oxycodone API powder
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oxycodone API powder (mass of 30 mg), containing oxycodone hydrochloride 30 mg.
Study: NCT03765346
Drug: Placebo to match oxycodone API powder
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo to match oxycodone API powder (mass of 30 mg).
Study: NCT03765346
Drug: Placebo to match manipulated oxycodone IR ADF.
DrugBank: Oxycodone (DB00497)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Placebo to match oxycodone IR ADF, manipulated (mass of 540 mg).
Study: NCT03382899
Drug: Pembrolizumab
Normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Pembrolizumab Alone
Study: NCT03273075
Drug: Cangrelor
Normalized name: Cangrelor
DrugBank: Cangrelor (DB06441)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The intervention comprises add-on Cangrelor infusion (administration in compliance with manufacturer instructions) in addition to and after administration of standard P2Y12-blocker (prasugrel or ticagrelor) therapy.
Study: NCT03273075
Drug: Prasugrel
Normalized name: Prasugrel
DrugBank: Prasugrel (DB06209)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: The intervention comprises the standard P2Y12-blocker prasugrel therapy if not contraindicated.
Study: NCT03273075
Drug: Ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The intervention comprises the standard P2Y12-blocker ticagrelor therapy if prasugrel is contraindicated and no contraindication to ticagrelor is present.
Study: NCT02588248
Drug: Peppermint Oil
Normalized name: Peppermint Oil
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: During the colonoscopy the Endoscopists will be required to deliver intraluminally 1 syringe at the cecum and 1 syringe in the sigmoid colon. Up to 2 additional doses can be delivered at the discretion of the endoscopist up to a maximum of 4 total doses (max total dose = 640 mg of L-Menthol).
Study: NCT02824380
Drug: DA-4001 H
Normalized name: DAS-181
DrugBank: DAS-181 (DB15313)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5% minoxidil / high dose of finasteride
Study: NCT02065869
Drug: Rimiducid
Normalized name: Rimiducid
DrugBank: Rimiducid (DB04974)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4mg/kg administered IV to treat GVHD